New hope for breast cancer brain metastases: drug combo plus radiation shows promise
NCT ID NCT07396454
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether adding two drugs (anlotinib and a tubulin inhibitor) to standard radiation therapy can help control HER2-negative breast cancer that has spread to the brain. About 39 women aged 18-70 will receive radiation followed by the drug combination. The main goal is to see how long the cancer in the brain stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anlotinib (a drug that blocks blood vessel growth) plus a tubulin inhibitor (a chemotherapy drug)
What this could lead to
If successful, this combination could offer a new treatment option to control brain metastases in HER2-negative breast cancer patients.
What could go wrong
This is a small, early-phase trial with only 39 participants, so results may not apply to everyone. The combination may cause side effects and might not improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, China
Contact Phone: •••-•••-••••